Human natural killer (NK) cell-based adoptive anti-cancer immunotherapy has gained intense interest with many clinical trials actively recruiting patients to treat a variety of both hematological malignancies and solid tumors. Most of these trials use primary NK cells isolated either from peripheral blood (PB-NK cells) or umbilical cord blood (UCB-NK cells), though these sources require NK cell collection for each patient leading to donor variability and heterogeneity in the NK cell populations. In contrast, NK cells derived human embryonic stem cells (hESC-NK cells) or induced pluripotent stem cells (hiPSC-NK cells) provide more homogeneous cell populations that can be grown at clinical scale, and genetically engineered if desired. These characteristics make hESC/iPSC-derived NK cells an ideal cell population for developing standardized, "off-the-shelf" immunotherapy products. Additionally, production of NK cells from undifferentiated human pluripotent stem cells enables studies to better define pathways that regulate human NK cell development and function. Our group previously established a stromal-free, two-stage culture system to derive NK cells from hESC/hiPSC in vitro followed by clinical-scale expansion of these cells using interleukin-21 expressing artificial antigen-presenting cells. However, prior to differentiation, this method requires single cell adaption of hESCs/hiPSCs which takes months. Recently we optimized this method by adapting the mouse embryonic fibroblast-dependent hESC/hiPSC to feeder-free culture conditions. These feeder-free hESC/hiPSCs are directly used to generate hematoendothelial precursor cells. This new method produces mature, functional NK cells with higher efficiency to enable rapid production of an essentially unlimited number of homogenous NK cells that can be used for standardized, targeted immunotherapy for the treatment of refractory cancers and infectious diseases.
Introduction:
Human natural killer (NK) cells are an important part of innate immune system with ability to kill malignant and virally infected cells without MHC-restriction and without prior sensitization 1 . NK cell cytotoxic activity against tumor cells or infected cells is mediated through a repertoire of germ-line encoded activating and inhibitory cell-surface receptors including killer-immunoglobulin receptors (KIRs), natural cytotoxicity receptors (NCRs) and the Fc Gamma receptor (FcγRIIIa) CD16a that mediates antibody-dependent cellular cytotoxicity (ADCC) 2, 3 . These important characteristics enable NK cells to function as allogeneic effector cells for treatment of refractory cancers and chronic infection diseases such as HIV.
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are ideal starting populations for the development of multiple cell lineages, including NK cells. hESC/iPSCs provide an model system to study the development NK cells in vitro 4, 5 . Previous studies from our group have shown that hESC/iPSC-derived NK cells have potent anti-tumor and anti-viral activities, providing a standardized cell-based treatment for these diseases [6] [7] [8] .
Multiple clinical studies now demonstrate NK cells can effectively treat acute myeloid leukemia (AML) and other malignancies while not causing serious adverse effects such as graft-versus-host disease (GvHD) or cytokine release syndrome (CRS) 9, 10 . To date, most of NK cell-based adoptive immunotherapy clinical trials have used primary NK cells isolated from donor's peripheral blood (PB-NK cells) 9, 10 , umbilical cord blood (UCB-NK cells) 11 or the transformed NK cell line NK-92 12 . While each have demonstrate clinical efficacy, there are some shortcomings 13 . For example, PB-NK cells and UCB-NK cells are typically a heterogeneous mix of NK cells and other immune cells that can vary from donor to donor 14 . NK-92 cells are aneuploid and need to be irradiated before use which limits the in vivo survival and expansion of these cells --as is known to be a key determinant of anti-tumor activity 12 . In contrast, hESC-NK cells and hiPSC-NK cells are more homogenous and can generate essentially unlimited cells sources suitable for clinical use 8 . Importantly, hESC/hiPSC-NK cells exhibit similar phenotype, transcriptome and functions as primary NK cells 6, 8 . Moreover, hESC/iPSC-NK cells can be routinely genetically modified by any of several methods including transposon and viral vectors 15 . Importantly, this genetic modification can be done on the undifferentiated pluripotent stem cells to produce a uniform population of NK cells with the desired effect. For example, the CRISPR/Cas9 or TALEN can be used to delete a gene of interest in hESCs or iPSCs to produce "knock-out" human NK cells. Key studies demonstrate the ability to utilize these genetic reporter systems expressed in hESCs and iPSCs to track and regulate development of specific blood cell lineages 4, 5, 16 .
The methods to generate NK cells from human pluripotent stem cells has evolved in the last decade 6, 17, 18 . Our initial studies used a stromal cell dependent two-stage culture system 6 . Briefly, to obtain CD34 + CD45 + hematopoietic progenitor cells, undifferentiated hESCs were cultured on stromal cell line (e.g. S17 or M2-10B4 cells) using media containing fetal bovine serum (FBS). Then hematopoietic progenitor cells were sorted and moved to a second stromal cell line (e.g. AFT024 or EL08-1D2 cells) in media supplemented with SCF, Fms-like tyrosine kinase 3 ligand (FLT3L), IL-3, IL-15, IL-7 to direct differentiation towards NK cells. Later, our group optimized the protocol by adapting a "spin-embryoid body (EB)" method to derive hematopoietic progenitor cells in defined serum-free, stromal-free conditions 8, 18 . After 11 days culture, hematopoietic progenitor cell-containing EBs were transferred to feeder-free plates in NK differentiation media containing SCF, FLT3L, IL-3, IL-15 and IL-7 for 4 weeks to generate CD45 + CD56 + NK cells. hESC-NK/iPSC-NK cells obtained using these methods express activating and inhibitory receptors similar to PB-NK cells 8 . More importantly, these NK cells exhibit potent antitumor and anti-viral activity both in vitro and in vivo. These functions include effective elimination of tumor cells xenografted in immune-deficient mice and inhibition of HIV-infected targets in an in vivo SCID-hu model 6, 7, 15, 19 . hESC-NK/iPSC-NK cells can be further expanded to clinical scale by using irradiated human stimulator cells, as previously utilized to effectively expand PB-NK or UCB-NK cells 20 . Notably, this method requires an essential single cell adaptation step to enable hESC/iPSC survival as single cells 18, 21 . This process is not uniform and typically requires 12-15 single cell passages that take several weeks.
Here, we describe an improved method for the derivation of NK cells from human pluripotent stem cells with higher efficiency and less time than existing protocols 18 . NK cells derived using this method have similar growth rate, phenotype and activity compared to PB-NK cells and UCB-NK cells generated by existing methods. In summary, this improved method allows efficient, rapid and reproducible production of hESC-/iPSC-NK cells from different pluripotent stem cell lines without the requirement of time-consuming single cell adaption process to facilitate clinical scale production and translation of hESC/iPSC-NK cells. Figure 1 provides a schematic diagram to compare the old and new methods. Prior to the generation of EBs, MEF-dependent undifferentiated hESC/iPSC are passaged on Matrigel-coated plates in mTeSR media (feeder free conditions) for 1 week, though this step is not needed for hESC/iPSC already maintained in feeder-free conditions. The feeder-free hESC/iPSC can be directly used to form EB in the presence of Rho-associated protein kinase inhibitor (ROCKi) which decreases the cellular stress response and the apoptotic cell death in stem cell cultures 22 . Indeed, these new conditions produce more hESC/iPSC-derived CD34 + hematopoietic progenitor cells in only 6 days (Figure 2 G). Following the generation of the hemato-endothelial precursor cells in the EBs, NK cell differentiation is supported using a stromal cell-free protocol similar to the existing protocol 18 .
Materials

Cell lines:
We have successfully produced NK cells from several different iPSC lines, including those derived from human fibroblasts (FiPSC), human peripheral blood mononuclear cells (PBiPSCs) 23 , or human CD34+ cells isolated from umbilical cord blood (UiPSC) 8 . Human ES cell line H9 was obtained from Wicell, Madison WI. K562 aAPC cells expressing membrane-bound IL-21 (Clone 9. mbIL-21) 20 were kindly provided by Dr. Dean Lee and Dr. Lawrence Cooper, MD Anderson Cancer Center, Houston, TX.
Cell culture media and reagents: Undifferentiated hESC and hiPSCs: culture in mTsER TM 1 (STEMCELL Technologies, Catalog # 85850).
K562 aAPC cells and Moml13 cells:
Culture in RPMI-1640 (ThermoFisher Scientific, Catalog #11875-085), 2 mM L-glutamine (ThermoFisher Scientific, Catalog #25030081), 10 % FBS, and 1 % penicillin/streptomycin (ThermoFisher Scientific,Catalog # 15140122); Spin EB differentiation medium: STEMdiff™ APEL™2 Medium (STEMCELL Technologies,Catalog # 05270). 18 Green Detection Reagent (Thermal Fisher Scientific, C10423); CellTrace™ Violet (Thermo-Fisher Scientific, C34557); S T X™ AADvanced™ dead cell stain solution (Thermal Fisher Scientific, S10349);
NK cell differentiation medium
Methods: Feeder free adaptation of feeder dependent hESC/iPSC
Before generating EBs, undifferentiated feeder-dependent hESC/iPSC need to be transferred to feederfree conditions with the use of mTeSR™1 on Matrigel (Corning) coated plates, as previously described 24 .
If hESC/iPSCs are already maintained on feeder-free conditions, skip this step. It is critical to make sure the hESC/iPSC are not differentiated before and after adaptation. This step will change the hESC/iPSC from clump culture to monolayer culture and increase efficiency of making single cell suspension. Cells should be able to adapt to feeder-free culture within 1 -2 passages and then exhibit morphology consistent with feeder-free human pluripotent stem cells ( Figure 2. A and B ). The following instructions are used for passaging cells from one well of a 6-well plate. 8. Carefully dissociate cells aggregates to single cell using 1 mL micropipette and transfer cells to a 15 mL conical tube. Add additional 5 ml medium (DMEM/F12 + 10%FBS). 9. Pass cell mixture through a 70 uM cell strainer to remove aggregates. 10 . Centrifuge cells at 300 x g for 5 minutes. 11. Aspire supernatant and wash cells once with 5 ml PBS. 12. Re-suspend cells with mTeSR™1 medium and plate cells 1 2 onto Matrigel pre-coated plate.
Cells can be used for spin EB formation when become confluent.
Generation of Hematopoietic Progenitor Cells from hES/iPS Cells by Spin EB Formation
Our group adapted a 'spin EB' protocol to generate hematopoietic progenitors 8, 21, 25 . Cells inside EBs can form endothelial and mesenchymal stromal cells to support following lymphocyte development, eliminating the use of xenogeneic stromal cells such as OP9 18 . While there is variability between different hESC and iPSC lines, we can consistently obtain >50% CD34+ cells for most of lines using this method ( Figure 2 ) (Note 1). The following instructions are used for collecting cells from one well of a 6well plate for EB formation.
1. 2 days before spin EB formation, pass 200,000 feeder free hESC/iPSCs onto 1 well of Matrigel coated 6-well plate which should reach 70-80 % confluence on the day of spin EBs set up. Generally 1 well of a 6-well plate are sufficient for 2 plates of spin EB.
Aspirate culture medium and detach cells by incubating with 1 ml incubating cells for 5 min at
37°C in pre-warmed TrypLE Select. 3. Carefully dissociate cells aggregates to single cell using 1 mL micropipette and transfer cells to a 15 mL conical tube. Add additional 5 ml medium (DMEM/F12 + 10%FBS). Pass cell mixture through a 70 uM cell strainer to remove aggregates. 4. Centrifuge cells, remove supernatant, wash cells once with 5 ml PBS. Then resuspend the cells in 1 ml APEL media.
Count cells and dilute cells to appropriate density using APEL media containing cytokines plus 10
uM ROCKi (Y-27632) to be used for plating. Typically, cells are seeded at 8000 cells/well in 100 ul media (80,000 cells/ml) in the 96-well plates (Note 2). 6. Pipet 100 μl of the cell suspension into 96-well plates using a multi-channel pipet. Centrifuge 96well plates at 300 x g for 5 minutes, and incubate the plates at 37 °C, 5 % CO2 for 6 days. We have found 6 days are enough to give rise to >50% CD34+ cells for most of hESC and iPSC lines. introducing cells and medium 2. Add 3 ml NK differentiation medium (as above) containing all of the cytokines to each well of gelatin-coated 6-well plate.
Derivation of human NK cells from spin EB
3. Spin EBs are directly transferred into 6-well plates on day 6. Carefully transfer EBs from 96-well plates to a 10 cm dish using 10 ml serological pipette and remove most of medium (Note 3). Then add 2 ml of NK differentiation medium containing all of the cytokines. Distribute 14-16 EBs into each well of the 6-well plate using 1 mL micropipette. Typically, EBs from 1 96-well plate can make 1 6-well NK differentiation plate. 4. Medium changes are done every 5-7 days (Note 4). Following the first week of the NK cell differentiation, IL-3 is no longer added to the media.
Continue medium changes for 3-4 weeks and check expression of NK cell makers (CD45+CD56+)
by flow cytometry on suspension cells (Figure 2 E-I) . Cells can be collected passing them through a 70-μm filter to remove any clumps when >80% of suspension cells are CD45+CD56+ (Note 5).
Expansion of hESC-/iPSC-Derived NK Cells to clinical scale
Typically, we can obtain 2-20 × 10 6 NK cells from 1 6-well plate. To further expand the NK cells for downstream applications, artificial antigen-presenting cells (aAPCs) are used to generate >10 9 NK cells ( Figure 3 ). 1. We use membrane-bound IL-21 expressing (mbIL-21) K562 cells 8, 20 as aAPCs to stimulate NK cell expansion. Before adding to NK cells, aAPCs are irradiated with 10,000 rads and made as frozen stocks. 2. After collecting from 6-well plate, NK cells are maintained in NK expansion medium containing 50 U/mL IL-2 (add freshly) at a density of 3 × 10 5 cells/mL. Irradiated aAPCs are thawed and added to NK cells at a ratio of 1:1. Media are changed every 3-4 days containing 50 U/mL of freshly added IL-2. 3. hESC-derived or iPSCs derived NK cells can be expanded for >3 months without a decrease in cell viability or cytolytic activity.
Phenotypic and functional characterization of hESC/iPSC-derived NK cells:
hESC/iPSC-derived NK cells can be phenotyped for surface antigens including CD56, CD45, CD16, NKG2D, NKp44, NKp46, TRAIL, FasL etc. We normally characterize phenotypes and killing activity of hESC/iPSC-derived NK cells after 3 weeks of expansion. Functions of NK cells can be accessed in vitro by measurement of direct cytolytic activity tumor cells (such as K562) by, 51 Cr-release, Caspase3/7 flow cytometric assay or immunological assays for cytotoxic granule or cytokine release. If desired, antitumor activity can be assessed in vivo using xenograft models 6, 19 . NK cells developed using this method show a mature NK cell phenotype and cytotoxicity (Figure 4 ). We are able to obtain >50% CD34+ cells for most of iPSC and ES lines tested using this method. We also found that EBs containing >10% CD34+ cells can be successfully differentiated to mature NK cells.
Note 2: 8000 cells/well works for most of cell lines. But the cell number can be optimized by individual investigators using different pluripotent stem cell lines depending on the growth rate of the cell line. We seed more cells than our previous protocol 18 (3000 cells/well) as we reduced the EB formation time from 11 days to 6 days.
Note 3:
It is critical to remove most of the medium and re-suspend with NK cell differentiation medium.
Note 4: After 14 days, medium needs to be changed every 3 days.
Note 5: It usually takes 4 weeks to obtain >90% CD45+CD56+ cells from spin EBs NK cells for most of ES or iPSC lines (Figure 2 ). Some cell line might only require 3 weeks and some line may take longer (about 5 weeks).
Result:
Single cell adaption of ESC/iPSC is not required for generation of hematopoietic progenitor cells and NK cells ur group adapted a 'spin EB' protocol to generate hematopoietic progenitors 8, 21, 25 . Cells inside EBs can form self-stromal cells to support following lymphocyte development, eliminating the use of xenoderived stromal cells such as OP9 18 . However, this method requires a single cell adaption process for ESC/iPSC which takes 2-3 months. To test whether the single cell adaption of ESC/iPSC is essential for generation of hematopoietic progenitor cells, we tried EB formation from human iPSC without single cell adaption (Figure 1 ). First, we culture the iPSCs without feeders for 1 week (Figure 2 A,B) . ROCKi was added to prevent cell death and help EB formation. Intact EBs can form from hiPSCs without single cell adaption (Figure 2 C, D) . Notably, most of cells in the EBs (day6) are CD34 + and about half of them are CD34 + CD45 + (Figure 2 G) . We then transferred day 6 EB to NK cell differentiation medium (see method section). After 7 days in NK cell differentiation medium, we found lots of round cells (suspension) around the EBs (Figure 2 E) . Most of the suspension cells were CD45 + CD56at this time point (Figure 2 H) . And most of the suspension cells become CD56+ after 28 days in NK cell differentiation medium ( Figure  2 F,I) . Together, these results demonstrated that Single cell adaption of ESC/iPSC is not required for generation of hematopoietic progenitor cells and NK cells.
Human ESC/iPSC derived NK cells using the new method are phenotypically mature and functional
We then generated NK cells from 2 iPSC lines (iPSC reprogrammed from umbilical CD34+ cells (UiPSC) and from fibroblast (FiPSC)) and 1 hESC line H9-derived NK cells using the new method described in Figure 1 . All the NK cells show similar growth rate when stimulating with aAPC weekly (Figure 3) . Importantly, hiPSC-derived NK cells using this method express NK cells receptors including NKG2D, NKp44, NKp46, TRAIL, FasL, similar to that of primary NK cells ( Figure 4A ). About 20% iPSC-NK cells were CD16+ which was consistent with previous publications. Moreover, hiPSC-derived NK cells show similar killing against tumor cells such as K562 and Molm13 ( Figure 4B ). These results demonstrated that Human ESC/iPSC derived NK cells using the new method are phenotypically mature and functional similar to primary NK cells.
Discussion
Here we optimized the method to derive NK cells from human ESC/iPSC. The improved method does not require the need to adapt ESC/iPSC to single cells, a process that takes 2-3 months. This new method takes about 5 weeks to generate large numbers mature NK cells from ESC/iPSC. Notably, hESC/iPSCderived NK cells using this method can be efficiently expanded to clinical scale. Importantly, these cells are phenotypically mature and functional similar to primary NK cells.
ROCK inhibition was reported to improve the cloning efficiency and survival upon dissociation of hES cells without altering their karyotype or pluripotency 26 . Here we used Y-27632, a specific inhibitor of Rho kinase (ROCK) activity, to help EB formation. Without Y-27632, most human ESC/iPSC without single cell adaption can't form intact EBs. In this new protocol, we transferred EB to NK cell differentiation medium at day 6 as most of cells in the EBs were CD34 + at this time point. Although most of cells were still CD45 -, they become CD45 + shortly after culturing in NK cell differentiation medium.
Cell-based therapies for treatment of relapsed/refractory cancers have been gaining in interest and importance. In addition to studies using CAR-T cells, clinical trials using NK cells isolated from peripheral blood or umbilical cord blood have been rapidly expanding 13 . However, these sources of NK cells are difficult to engineer and vary from donor to donor. iPSC-derived NK cells are being translated to clinical trials to now provide a standardized, "off-the-shelf" therapy that can be routinely engineered to target and better treat relapsed/refractory malignancies 13 . The improved method allows efficient, rapid and reproducible production of hESC-/iPSC-NK cells from different pluripotent stem cell lines without the requirement of time-consuming single cell adaption process thus facilitate clinical scale production and translation of hESC/iPSC-NK cells. Figure 1. Schematic diagram of new method (A.) and old method 18 (B.) for in vitro NK cell differentiation from human embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC). Briefly, the old method requires a single cell adaption process for ESC/iPSC which takes 2-3 months. While the new method starts with feeder free adapted ESC/iPSC and use ROCKi to help EB formation. Both methods use spin EBs (11 days for old method and 6 days for the new method) to generate hematopoietic progenitor cells (CD34+ cells). Then EBs are directly transferred into NK cell differentiation conditions. Mature and functional NK cells will develop after 3-5 weeks and can be expanded using IL2 and aAPCs. 
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